Unknown

Dataset Information

0

Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19.


ABSTRACT:

Background

Hypercoagulability may be a key mechanism of death in patients with coronavirus disease 2019 (COVID-19).

Objective

To evaluate the incidence of venous thromboembolism (VTE) and major bleeding in critically ill patients with COVID-19 and examine the observational effect of early therapeutic anticoagulation on survival.

Design

In a multicenter cohort study of 3239 critically ill adults with COVID-19, the incidence of VTE and major bleeding within 14 days after intensive care unit (ICU) admission was evaluated. A target trial emulation in which patients were categorized according to receipt or no receipt of therapeutic anticoagulation in the first 2 days of ICU admission was done to examine the observational effect of early therapeutic anticoagulation on survival. A Cox model with inverse probability weighting to adjust for confounding was used.

Setting

67 hospitals in the United States.

Participants

Adults with COVID-19 admitted to a participating ICU.

Measurements

Time to death, censored at hospital discharge, or date of last follow-up.

Results

Among the 3239 patients included, the median age was 61 years (interquartile range, 53 to 71 years), and 2088 (64.5%) were men. A total of 204 patients (6.3%) developed VTE, and 90 patients (2.8%) developed a major bleeding event. Independent predictors of VTE were male sex and higher D-dimer level on ICU admission. Among the 2809 patients included in the target trial emulation, 384 (11.9%) received early therapeutic anticoagulation. In the primary analysis, during a median follow-up of 27 days, patients who received early therapeutic anticoagulation had a similar risk for death as those who did not (hazard ratio, 1.12 [95% CI, 0.92 to 1.35]).

Limitation

Observational design.

Conclusion

Among critically ill adults with COVID-19, early therapeutic anticoagulation did not affect survival in the target trial emulation.

Primary funding source

None.

PROVIDER: S-EPMC7863679 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC7396456 | BioStudies
| S-EPMC8425807 | BioStudies
| S-EPMC7425668 | BioStudies
| S-EPMC8024143 | BioStudies
| S-EPMC8250316 | BioStudies
| S-EPMC9243575 | BioStudies
| S-EPMC8812085 | BioStudies
| S-EPMC7537137 | BioStudies
| S-EPMC7942819 | BioStudies
| S-EPMC8769106 | BioStudies